{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "The adjusted EBITDA margin as a percentage of revenue decreased from 18% in 2022 to 7% in 2023 for the Degree Program Segment.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "The level of impairment charges for goodwill in the Degree Program Segment decreased from $35.7 million in 2022 to $19.6 million in 2023, while in the Alternative Credential Segment, it increased from $50.2 million to $62.8 million over the same period.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "From 2022 to 2023, FCE enrollments increased in the Degree Program Segment and decreased in the Alternative Credential Segment.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": " Great! I'm glad I could assist in that. Is there anything else you need help with?", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": " impairments to intangible assets charged to operating expenses in 2021 and 2022 were:\n\n* 2021: $700,000\n* 2022: $650,000", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "The operating income for Healthcare Solutions decreased from $35.3 million in 2021 to $26.3 million in 2022, while the operating income for Industrial Solutions increased from $27.7 million in 2021 to $35.8 million in 2022.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "Block, Inc. earned $22.7 million in interest income from customer funds in 2023, compared to $17.3 million in 2022 and $11.5 million in 2021.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. reorganized its business structure and reported its financial results in two reportable segments - Square and Cash App. Previously, the financial results of the BNPL platform were included solely within the Cash App segment. With the reorganization, the financial results of the BNPL platform are now presented separately. This change in organizational structure affected the allocation of BNPL platform financial results as follows:\n\n* The total revenue generated by the BNPL platform for the year ended December 31, 2023 was $17.531,587.\n* The total revenue generated by the BNPL platform for the year ended December 31, 2022 was $10.540,747.\n* The total revenue generated by the BNPL platform for the year ended December 31, 2021 was $6.597,608.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "As of December 31, 2022, the fair value of the Company's consumer receivables portfolio was estimated to be $1,972 million, with $1,369 million classified as current and $603 million as non-current, net of allowance for credit losses of $77.3 million. By December 31, 2023, the portfolio had grown to $2,417 million, with $1,727 million classified as current and $690 million as non-current, net of an allowance for credit losses of $76.5 million.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The percentage change in net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023, was 1.9%.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "In 2023, C.H. Robinson Worldwide, Inc. (\"C.H. Robinson\" or the \"Company\") experienced a decrease in net income due to weaker freight demand and excess carrier capacity, which led to lower pricing in the surface transportation and global forwarding markets. This resulted in a decrease in adjusted gross profits, which measure the Company's core operating profitability excluding certain non-recurring items and transaction-related costs. The Company's North American surface transportation (\"NAST\") segment, which contributes the majority of its revenue, experienced a decrease in adjusted gross profit per shipment, reflecting the softening freight market. Additionally, certain one-time items, such as restructuring charges related to a South American restructuring program and costs related to the 2022 Restructuring Program, negatively impacted the Company's results. Despite these challenges, C.H. Robinson maintained its strong operating cash flow and ended the year with a solid balance sheet, reflecting its long-term growth strategy and commitment to creating shareholder value.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The revenue recognition policy related to in-transit shipments was updated to reflect the Company's ability to recognize revenue over the transit period, rather than solely at the completion of the shipment. However, the Company had already been accounting for in-transit shipments this way prior to the policy update.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "Stock-based compensation expense for the year ended December 31, 2023, was $89.2 million, and as of that date, the Company had $176.1 million of unrecognized compensation cost related to non-vested stock-based compensation arrangements.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses decreased from $85.2 million in 2022 to $74.1 million in 2023. This decrease was primarily driven by reduced spending on research and development projects related to early-stage product candidates and decreased investment in clinical trials for these candidates. Additionally, the Company reduced expenses related to certain joint research and development projects due to the termination of collaborations or reduction in scope.\n\nSales and marketing expenses increased from $161.5 million in 2022 to $201.8 million in 2023. This increase was primarily due to increased spending on marketing and promotional activities, including the launch of new products and increased investment in branding and advertising campaigns. The Company also expanded its sales force and invested in technology and data analytics to improve sales and customer engagement. These changes were driven by the Company's continued expansion into new markets and products, as well as increased competition in the healthcare industry.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporationâ€™s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "At the end of 2023, Exact Sciences Corporation's cash and cash equivalents totaled $561,587,000, compared to $658,907,000 at the beginning of the year. The primary factors contributing to this decrease were:\n\n1. **Change in accounts receivable:** The decrease of $107,103,000 in accounts receivable was primarily due to a decrease in diagnostic and clinical services accounted for, as well as a decrease in other accounts receivable.\n2. **Capex purchase:** The Company incurred $110,493,000 for the purchase of technology from CimaBio Group AG, which was funded using cash on hand. This acquisition contributed to the decrease in cash and cash equivalents.\n3. **Operating activities:** The net cash used in operating activities for the year ended December 31, 2023, was $311,274,000, compared to $207,864,000 for the year ended December 31, 2022. This increase was primarily due to an increase in net losses, primarily driven by an increase in research and development expenses.\n\nThe above factors contribute to the overall decrease in cash and cash equivalents for the Company.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by approximately $58.6 million, or 114.4%, from $51.1 million in 2022 to $109.7 million in 2023. Additionally, the Company recognized collaboration revenue of $37.2 million and $18.2 million for the years ended December 31, 2023 and December 31, 2022, respectively.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss increased from $(209.2) million in 2022 to $(233.6) million in 2023. The increase was primarily driven by higher research and development expenses, increased selling, general and administrative expenses, and higher interest expense.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "In 2022, the net product sales for NEXLETOL and NEXLIZET were $55.9 million and $11.3 million, respectively, and the collaboration revenue was $18.2 million. In 2023, the net product sales for NEXLETOL and NEXLIZET were $78.3 million and $75.9 million, respectively, and the collaboration revenue was $32.6 million.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "Increases in net revenue for Property & Casualty insurance were offset by an increase in customer acquisition spend in order to maintain customer retention and growth.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In 2023, Open Marketplace transactions generated $378.7 million, while Private Marketplace transactions generated $90.4 million.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue, which represents a significant portion of the Company's total revenue, was one of the main factors contributing to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Regulatory changes in the EU, such as those related to data exclusivity and medical device regulations, could potentially impact Mind Medicine's operations in Europe. Here are some potential effects:\n\n1. **Data Exclusivity**: Changes to data exclusivity regulations could impact Mind Medicine's ability to rely on a certain period of marketing exclusivity for its medicinal products in the EU. If data exclusivity periods are shortened or modified, it may affect Mind Medicine's ability to maintain or increase market share and-revenue in Europe.\n2. **Medical Device Regulations**: Changes to medical device regulations could impact the way Mind Medicine's products, such as its digital medicine devices and accessories, are classified, approved, and marketed in the EU. For example, changes to regulations regarding software as a medical device (SaMD) or new classification rules could require Mind Medicine to obtain additional or different approvals, which could delay or increase the costs of bringing its products to market in the EU.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "11.2 million shares of Common Stock and 10.0 million shares of Series B Preferred Stock.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "If the company fails to comply with controlled substance laws and regulations during the development of its product candidates, it could face legal and regulatory consequences, including fines, penalties, or even the loss of its license to operate. Additionally, if the company's products are found to contain controlled substances that were not properly handled, it could face lawsuits from individuals injured by those products. Finally, if the company's handling of controlled substances is found to be inadequate, it could damage its reputation and hinder its ability to obtain future licenses or approvals.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "A single customer accounted for 13% of NVIDIA's total revenue for fiscal year 2024, which was attributable to the Compute & Networking segment. While this concentration may not pose an immediate threat, it could impact the company's financial performance if this customer reduces or discontinues their business with NVIDIA.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "Between January 29, 2023 and January 28, 2024, NVIDIA's net income increased by $30,368 million, while their revenue increased by $34,947 million. This represents an increase in net margin from 12% to 13%.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "During fiscal year 2024, sales to one customer represented 13% of total revenue for theCompute & Networking segment.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": false, "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": false, "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": false, "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "Increased demand for electric vehicles, production challenges, and changes in pricing strategies.\n\n 1. **Increased Demand for Electric Vehicles**: The global shift towards electric vehicles (EVs) has boosted demand for Tesla's products. This increase in demand contributed to higher automotive sales revenue.\n 2. **Production Challenges**: Despite increased demand, Tesla faced production and supply chain challenges in 2022, leading to a decrease in vehicle production and deliveries compared to 2021. In 2023, Tesla resolved many of these challenges, resulting in increased production and deliveries.\n 3. **Changes in Pricing Strategies**: Tesla implemented higher pricing strategies for its vehicles in response to increased production costs and logistical challenges, which positively impacted automotive gross margin in 2023 compared to 2022.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "Tesla's short-term investments and inventory increased by $194 million and $7.1 billion, respectively, from December 31, 2022, to December 31, 2023.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla's commitments for capital expenditure and tax revenues in the state of New York include:\n\n* Estimated cumulative capital expenditure of $3.5 billion through 2026.\n* Proposed to create 1,000 new jobs and retain 1,500 existing jobs in the state.\n\nMeanwhile, Tesla's Gigafactory 3 project in Shanghai, China has commitments for:\n\n* A planned investment of RMB 14.08 billion ($2.1 billion) for phase one of the project.\n* An expected creation of 10,000 jobs in the first phase of the project.\n\nThus, the capital expenditure commitments in New York are much larger than those in Shanghai, while the jobs commitment in Shanghai is higher than that in New York. Tax revenue commitments are not explicitly stated in the provided information about Shanghai.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
